Oric Pharmaceuticals (ORIC) Net Income towards Common Stockholders (2019 - 2026)
Oric Pharmaceuticals (ORIC) posted Net Income towards Common Stockholders of -$140.3 million for Q1 2026, down 308.07% on a QoQ basis from -$34.4 million in Q4 2025, and down 214.38% year-over-year from $122.7 million in Q1 2025.
Oric Pharmaceuticals (ORIC) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Oric Pharmaceuticals' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$140.3 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 214.38% year-over-year to -$140.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$386.7 million (up 4.62% YoY) and the FY2025 annual result came in at -$355.2 million, down 12.64% from the prior year.
- Net Income towards Common Stockholders was -$140.3 million for Q1 2026 at Oric Pharmaceuticals, down from -$34.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$21.8 million in Q4 2022 and bottomed at -$212.5 million in Q4 2024.
- A 5-year average of -$77.4 million and a median of -$54.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders slumped 650.63% — and 2025, when it soared 83.82%.
- Oric Pharmaceuticals' Net Income towards Common Stockholders stood at -$21.8 million in 2022, then slumped by 650.63% to -$163.8 million in 2023, then retreated by 29.74% to -$212.5 million in 2024, then surged by 83.82% to -$34.4 million in 2025, then plunged by 308.07% to -$140.3 million in 2026.
- Business Quant data shows ORIC's Net Income towards Common Stockholders at -$140.3 million in Q1 2026, -$34.4 million in Q4 2025, and -$116.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | -0.68 |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Oric Pharmaceuticals | 1.30 Bn | 1.30 Bn | - | -140.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -140.30 Mn |
| Dec 31, 2025 | -34.38 Mn |
| Sep 30, 2025 | -116.54 Mn |
| Jun 30, 2025 | -95.44 Mn |
| Mar 31, 2025 | -44.63 Mn |
| Dec 31, 2024 | -212.48 Mn |
| Sep 30, 2024 | -89.08 Mn |
| Jun 30, 2024 | -59.21 Mn |
| Mar 31, 2024 | -118.61 Mn |
| Dec 31, 2023 | -163.77 Mn |
| Sep 30, 2023 | -43.70 Mn |
| Jun 30, 2023 | -54.56 Mn |
| Mar 31, 2023 | -37.82 Mn |
| Dec 31, 2022 | -21.82 Mn |
| Sep 30, 2022 | -28.50 Mn |
| Jun 30, 2022 | -25.57 Mn |
| Mar 31, 2022 | -29.44 Mn |
| Dec 31, 2021 | -23.29 Mn |
| Sep 30, 2021 | -66.20 Mn |
| Jun 30, 2021 | -57.13 Mn |